A3 - Beyond COVID – Catalysing vaccine technology and drug delivery

Madrid

Organised in collaboration with FIP’s Hospital Pharmacy Section

Chair(s)

Mr Jaime Acosta-Gomez (Spain)
Assoc Prof Michael Ward (Australia)

Introduction

The pace of development of COVID-19 vaccines has been nothing short of a modern miracle. There is, perhaps, no bigger story than the transition of mRNA technologies from relatively small-scale experimental approaches to clinical implementation on a grand scale. This experience has stimulated increased interest in the development of other technologies that have followed a similar development history to mRNA. This session will explore some of these technologies in the management of conditions beyond COVID and consider the implications for health care.

 

 

 

Programme

14:00 – 14:10      Introduction by the chair 

14:10 – 14:35

 

Overview of mRNA COVID-19 vaccine, cell-based gene therapy, and future oncology therapeutics development
Dr Josep Maria Guiu Segura, Consortium of Health and Social Care of Catalonia, Spain

14:35 – 15:00

 

Title to be confirmed
Dr Gustavo Mendes Lima Santos, Anvisa, Brazil

15:00 – 15:20   Q&A 
     
15:20 – 15:30

 

Conclusion by the chair 

Learning Objectives

  1. To describe mRNA vaccine technology
  2. To describe emerging technologies such as cell-based therapy
  3. To describe therapeutic applications of mRNA and cell-based therapy beyond COVID-19
  4. To discuss the potential implications of these technologies for health care
Back to top